EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non–Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials

BACKGROUND: Results of several randomized clinical trials (RCTs) testing the combination of an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) plus an anti-angiogenic drug in advanced EGFR-mutated non–small cell lung cancer were reported. METHODS: We first report a systematic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JNCI Cancer Spectr
Main Authors: Conforti, Fabio, Pala, Laura, Bagnardi, Vincenzo, Specchia, Claudia, Oriecuia, Chiara, Marra, Antonio, Zagami, Paola, Morganti, Stefania, Tarantino, Paolo, Catania, Chiara, De Marinis, Filippo, Queirolo, Paola, De Pas, Tommaso
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Meta-Analysis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7737478/
https://ncbi.nlm.nih.gov/pubmed/33344882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkaa064
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares